BioCryst Pharma Cancels Planned Public OfferingALK inhibitors, Biopharma Companies, Business, Hereditary Angioedema (HAE), Product Pipeline, Rare DiseasesBioCryst Pharmaceuticals, a global biopharmaceutical company that focuses on developing treatments for rare diseases, canceled plans to hold a public offering to raise funds. Read more August 11, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/08/BioCryst-Pharma-Cancels-Planned-Public-Offering-Says-Funds-Are-Sufficient-BioSpace-8-11-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-08-11 14:33:362021-08-11 16:41:23BioCryst Pharma Cancels Planned Public Offering